United Therapeutics (UTHR)
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
$598.72+0.87%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
Research Workspace
Put UTHR beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Maintain strong operating income: Comparison needs review.
View ThesisRevenue growth is slowing — up about 2% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 9%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskUTHR’s case rests on strong financial performance and new treatment approvals. Revenue fell 2% year over year in Q2 FY2026, after the same decline in Q1. Q2 earnings beat estimates, but revenue missed expectations. UTHR trades at 21× P/E, versus 22× for peers and 19× historically. The price reflects less growth than our forecast. A next-quarter earnings miss remains a 30% risk. Its operating-income pillar needs review because the comparison is unverified. Peer multiples imply a price roughly in line with where it trades (about fair). The thesis is on watch; this read is provisional.
Trailing returns as of 2026-10-30. UTHR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering UTHR (as of Oct 2026).
Based on 8 Wall Street analysts offering 12-month price targets for UTHR in the last 4 months.
Continue this research
Compare UTHR with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| UTHR Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put UTHR next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance regulatory approvals for ralinepag and nebulized Tyvaso
FDA clearance advances clinical development, but trial approval is not product approval.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $598.72
The last 12 months of price, then the range of analyst 12-month targets from today’s $598.72.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Execute $2 billion share repurchase program
Additional $2B repurchase plan advances capital returns, though execution and funding remain to be assessed.
Advances: Advance organ manufacturing pipeline and xeno-organ production facilities
Third xenograft facility expands organ-production capacity and advances the manufacturing pipeline.
Patent resolution may impact competitive landscape for UTHR.
Settlement reduces legal risks, supporting growth objectives.
Court ruling positively impacts competitive landscape.
Advances: Advance regulatory approvals for ralinepag and nebulized Tyvaso in new indicati…
Indicates positive outlook for regulatory approvals and growth.
Advances: Execute $2 billion share repurchase program
Buyback supports capital allocation strategy and shareholder value.
